TMCI Stockholder Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Treace Medical Concepts, Inc.

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Treace Medical failed to disclose competition affecting the demand for its primary product, resulting in a revenue decline [2]. - Following the revelation of these issues, Treace Medical's stock price dropped nearly 63%, closing at $4.17 per share on May 8, 2024 [2]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by June 10, 2025 [3]. - Shareholders can choose to remain absent class members without participating in the case [3]. Group 3: Company Background - Treace Medical Concepts, Inc. focuses on advancing surgical management standards for bunion and related midfoot deformities [1].